Folic acid-tethered pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: Conformational characterization and in vitro cellular uptake evaluation

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1155-1165

  Kang, Myung Joo ^a   Park, Sang Han ^a   Kang, Mean Hyung ^a   Park, Min Jung ^a   Choi, Young Wook ^a  

^a Chung Ang University   (South Korea)

Author keywords

Cell penetrating peptide; Folic acid; Intracellular delivery; Liposome; Pep 1 peptide; Targeted delivery

Indexed keywords

DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DRUG CARRIER; ETHANOLAMINE DERIVATIVE; FLUORESCEIN DEXTRAN ISOTHIOCYANATE; FOLATE RECEPTOR; FOLIC ACID; ISOTHIOCYANIC ACID DERIVATIVE; LIPOSOME; MACROGOL 2000; MALEIMIDE DERIVATIVE; NANOCARRIER; PENETRATING PEPTIDE; PEP 1 PEPTIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL STRAIN; CHEMICAL PARAMETERS; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CONFORMATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; HACAT CELL; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID VESICLE; PARTICLE SIZE; POLYDISPERSITY INDEX; SPECTROPHOTOMETRY; ZETA POTENTIAL;

CELL-PENETRATING PEPTIDE; FOLIC ACID; INTRACELLULAR DELIVERY; LIPOSOME; PEP-1 PEPTIDE; TARGETED DELIVERY;

AMINO ACID SEQUENCE; CELL LINE, TRANSFORMED; CELL SURVIVAL; CYSTEAMINE; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; FOLIC ACID; HELA CELLS; HUMANS; INTRACELLULAR SPACE; KERATINOCYTES; LIPOSOMES; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; PROTEIN CONFORMATION;

EID: 84875152889     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39491     Document Type: Article

References (36)

1. Torchilin V P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2006;8:343-375.
2. Goncalves E, Kitas E, Seelig J. Binding of oligoarginine to membrane lipids and heparan sulfate: structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry. 2005;44(7):2692-2702.
3. Herbig ME, Weller KM, Merkle H P. Reviewing biophysical and cell biological methodologies in cell-penetrating peptide (CPP) research. Crit Rev Ther Drug Carrier Syst. 2007;24(3):203-255.
4. Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol. 2002;62(4):864-872.
5. Torchilin V P, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their effcient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A. 2001;98(15):8786-8791.
6. Kang MJ, Kim BG, Eum JY, et al. Design of a Pep-1 peptide-modifed liposomal nanocarrier system for intracellular drug delivery: Conformational characterization and cellular uptake evaluation. J Drug Target. 2011;19(7):497-505.
7. Vivès E, Schmidt J, Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008;1786(2):126-138.
8. Myrberg H, Zhang L, Mäe M, Langel U. Design of a tumor-homing cell-penetrating peptide. Bioconjug Chem. 2008;19(1):70-75.
9. Mäe M, Myrberg H, El-Andaloussi S, Langel U. Design of a tumor homing cell-penetrating peptide for drug delivery. Int J Pept Res Ther. 2009;15(1):11-15.
10. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004;101(51):17867-71772.
11. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release. 2007;118(2):216-224.
12. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev. 1999;8(9): 770-782.
13. Elnakat H, Rantnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56(8):1067-1084.
14. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissue. Cancer Res. 1992;52(12):3396-3401.
15. Ross J F, Wang H, Behm FG, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 1999;85(2):348-357.
16. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood. 2002;100(2):594-602.
17. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41(2):147-162.
18. Zhao XB, Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv Drug Deliv Rev. 2004;56(8):1193-1204.
19. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233(2): 134-144.
20. Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem. 1999;10(2):289-298.
21. Nagarsenker MS, Londhe V Y, Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm. 1999;190(1):63-71.
22. Cornell BA, Middlehurst J, Separovic F. The molecular packing and stability within highly curved phospholipid bilayers. Biochim Biophys Acta. 1980;598(2):405-410.
23. Xiang G, Wu J, Lu Y, Liu Z, Lee RJ. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int J Pharm. 2008; 356(1-2):29-36.
24. Leamon C P, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A. 1991;88(13):5572-5576.
25. Wang S, Luo J, Lantrip DA, et al. Design and synthesis of [111In] DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug Chem. 1997;8(5):673-679.
26. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269(5): 3198-3204.
27. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodefciency virus tat trans-activator protein. Cell. 1988;55(6):1179-1188.
28. Pooga M, Hällbrink M, Zorko M, Langel U. Cell penetration by transportan. FASEB J. 1998;12(1):67-77.
29. Maiolo JR, Ferrer M, Ottinger EA. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta. 2005;1712(2):161-172.
30. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A. 1991;88(5):1864-1868.
31. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001;19(12):1173-1176.
32. Sawant RM, Hurley J P, Salmaso S, et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006;17(4):943-949.
33. Elmquist A, Lindgren M, Bartfai T, Langel U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res. 2001;269(2):237-244.
34. Stella B, Marsaud V, Arpicco S, et al. Biological characterization of folic acid-conjugated poly(H2NPEGCA-co-HDCA) nanoparticles in cellular models. J Drug Target. 2007;15(2):146-153.
35. Deshayes S, Heitz A, Morris MC, Charnet P, Divita G, Heitz F. Insight into the mechanism of internalization of the cell-penetrating carrier pep-tide Pep-1 through conformational analysis. Biochemistry. 2004;43(6): 1449-1457.
36. Henriques ST, Castanho MA. Translocation or membrane disintegration? Implication of peptide-membrane interactions in pep-1 activity. J Pept Sci. 2008;14(4):482-487.